Blueprint Medicines

Blueprint Medicines (NASDAQ: BPMC) was founded in April 2011, with its headquarters in Cambridge, Massachusetts, USA. The company has 106 full-time employees and was established with funding from Third Rock Ventures. Blueprint Medicines (BPMC) envisions transforming the acute symptoms of cancer into acceptable and manageable subacute conditions through medication, thereby improving the lives and quality of life for cancer patients. To achieve this goal, BPMC is systematically developing highly selective drugs and drug combinations (kinase inhibitors) derived from revolutionary advances in cancer genomics to combat resistance mechanisms in cancer. Blueprint Medicines boasts a world-class management, advisory, and R&D team in the fields of cancer genomics, pharmacology, and oncology. It has developed a platform that integrates cancer genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent and highly selective chemical drugs targeting cancer genomics.